UNSPSC 51384103: Butibufen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H20O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JSS1TEM917, chemically known as butyric acid, 2-(4-isobutylphenyl)- but generally known as butibufen, which bears US NIH Compound Identifier 41643. European Medicines Agency schedules Butibufen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06015MIG.

UNSPSC 51384103 Butibufen is a Commodity code that covers pharmaceutical products, though recent state and local solicitations tagged under this code do not consistently align with butibufen specifically. Instead, the code appears in procurement notices for naloxone distribution, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. State and local governments use this code to solicit bulk pharmaceutical purchases for community health initiatives, pharmacy benefit programs, and distributed health systems. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances serving multi-state government jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The work involves procurement of pharmaceutical products with specific national drug codes, establishment of wholesaler relationships, and compliance with federal manufacturing and supply-chain security standards including cGMP and Drug Supply Chain Security Act certification.

Geographic activity centers on Florida, Texas, and Minnesota, with multi-state scope through cooperative purchasing mechanisms. Recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 annual units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to Sanford, Florida; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) gathering market intelligence on direct-to-manufacturer prescription program capabilities; and the Minnesota MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson wholesalers to state and local facilities across Minnesota and Oregon. The MMCAP procurement weights price competitiveness at 75 percent and requires vendors to maintain two-of-three authorized wholesaler relationships with chargeback systems, comply with FDA requirements, and carry $5 million commercial general liability insurance.